Icatibant Medicine 09 January 2018 Extended indication Voor de behandeling van de symptomen van aanvallen van erfelijk angio-oedeem bij jongeren en kinderen ouder dan twee jaar. Therapeutic value No judgement Total cost Registration phase Unknown Product Active substance Icatibant Domain Chronic immune diseases Reason of inclusion Main indication Other chronic immune diseases Extended indication Voor de behandeling van de symptomen van aanvallen van erfelijk angio-oedeem bij jongeren en kinderen ouder dan twee jaar. Current proprietary name Already available biosimilars / generics Proprietary name Firazyr Manufacturer Shire Portfolio holder Mechanism of action Unknown Route of administration Subcutaneous Therapeutical formulation Injection Budgetting framework Extramural (GVS) Centre of expertise Additional remarks Registration Registration route Centralised (EMA) Type of trajectory Unknown Particularity Unknown ATMP Unknown Submission date Expected Registration October 2017 Orphan drug No Registration phase Unknown Reimbursement Medicine sluice Additional remarks Indicatie-uitbreiding. Geregistreerd in oktober 2017. Therapeutic value Current treatment options Therapeutic value No judgement This assessment does not indicate any potential inclusion in the package. Substantiation Duration of treatment Frequency of administration Dosage per administration 30 mg References Additional remarks Expected patient volume per year Patient volume Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References Additional remarks Expected cost per patient per year Cost € 1,500.00 - 1,700.00 This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year. References Medicijnkosten.nl Additional remarks €1678,33 per injectie van 30 mg Potential total cost per year Total cost Total cost for sluice Additional remarks Off label use Off label use Unknown Indications off label use References Additional remarks Indication extension Indication extensions Unknown Indication extensions References Additional remarks Other information Additional remarks